Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Type 1 Diabetes

Therapeutic area intelligence for Type 1 Diabetes with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
10
Catalysts
0
Companies
2

Companies

COUR Pharmaceutical →
Sanofi →

Assets

CNP-103 →
Cognitive →
Endocrinology →
Medtronic →
TZIELD →

Recent signals(10)

ClinicalAugust 2, 2026

Cognitive Behavioral Intervention Study for Type 1 Diabetes Launched

A new clinical trial is investigating the impact of a cognitive behavioral intervention on lifestyle and glucose management in adults with type 1 diabetes.

RegulatoryJuly 28, 2026

FDA Grants Priority Review for TZIELD (Teplizumab) Supplement

The FDA has granted priority review status for the supplemental Biologics License Application (BLA) for TZIELD (teplizumab) submitted by Provention Bio.

ClinicalJuly 23, 2026

Trial to Assess Recruitment Methods for Type 1 Diabetes Screening

A clinical trial is evaluating the effectiveness of different recruitment communication methods for type 1 diabetes screening.

RegulatoryJuly 5, 2026

FDA Grants Priority Review for TZIELD (Teplizumab-MZWV) Supplement

The FDA has granted priority review for the supplemental application of TZIELD (Teplizumab-MZWV) by Provention Bio.

ClinicalJuly 4, 2026

MyDiaMate Study Aims to Alleviate Diabetes Distress in Type 1 Diabetes

The MyREMEDY study evaluates the effectiveness of the MyDiaMate app in improving mental health for adults with type 1 diabetes.

ClinicalJuly 3, 2026

Phase 1b/2a Trial of CNP-103 for Stage 3 Type 1 Diabetes Initiated

COUR Pharmaceutical has initiated Phase 1b/2a clinical trial for CNP-103 in adolescents and adults with recently diagnosed Stage 3 Type 1 Diabetes.

ClinicalJune 24, 2026

Study on Carbohydrate Intake Impact in Type 1 Diabetes with Advanced Hybrid Closed-loop System

A study is evaluating the impact of daily carbohydrate intake on glycemic control in youth with type 1 diabetes using an advanced hybrid closed-loop system.

ClinicalJune 21, 2026

Study on Sleep Regularity's Impact on Glycemic Control in Type 1 Diabetes

A mechanistic study will explore how improving sleep regularity affects glycemic control and cardiovascular risk in individuals with type 1 diabetes.

RegulatoryJune 20, 2026

FDA Grants Priority Review for TZIELD (Teplizumab) Supplement

The FDA has granted priority review for the supplemental application of TZIELD (Teplizumab) by Provention Bio.

RegulatoryJune 16, 2026

FDA Approves Tzield for Pediatric Patients with Stage 3 Type 1 Diabetes

The FDA granted accelerated approval for Tzield (teplizumab) to delay insulin production decline in pediatric patients with Stage 3 T1D.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Type 1 Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.